Day Zero Diagnostics announced that it received an $8.2 million award in optional stage funding from CARB-X.
The infectious disease diagnostic developer received an initial $6.2 million CARB-X award in May 2020. CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, aims to accelerate early antibacterial R&D. This would address the rising global threat of drug-resistant bacteria.
Day Zero’s total award funding now sits at more than $16 million. The company also completed a venture equity financing worth $21 million in February.
Anti-biotic-resistant infections remain on the rise. Worries persist that superbugs could eventually evolve to the point that antibiotics no longer work effectively. In 2020, more than 20 biopharmaceutical companies around the world pledged more than $1 billion toward the Antimicrobial Resistance (AMR) Action Fund.
Day Zero develops whole genome sequencing-based diagnostic technologies.…